Diagnóstico e tratamento da deficiência de testosterona: uma revisão / Diagnosis and treatment of testosterone deficiency: a review

Bernardo Passos Sobreiro

Abstract


Introdução: a deficiência de testosterona (DT), é uma condição que pode afetar até 38% dos homens tendo um impacto fortemente negativo na qualidade de vida. O diagnóstico e tratamento da DT podem representar um desafio para o clínico, sendo necessário um conhecimento atualizado da literatura. Objetivo: revisar a literatura disponível com o intuito de fornecer informações clínicas relevantes para o manejo da DT. Método: realizamos uma busca nas bases de dados do PubMed, Google Acadêmico e Cochrane usando os termos testosterona e deficiência, hipogonadismo, diagnóstico, tratamento, efeitos colaterais, síndrome metabólica, disfunção erétil, câncer de próstata e doenças cardiovasculares. O período da busca foi de janeiro de 1995 a março de 2022.Resultados: foram estabelecidas recomendações para as seguintes áreas da DT: critérios de diagnóstico (clínico e laboratorial), efeitos benéficos da DT no tratamento da disfunção erétil, diabetes e obesidade. Os efeitos colaterais mais observados na DT foram a infertilidade e eritrocitose. Não identificamos trabalhos que associassem a reposição de testosterona (TRT) com o câncer de próstata. Existem poucos trabalhos que demonstraram haver risco para doenças cardiovasculares na TRT. De fato, existem muitos estudos que descreveram redução no risco de infarto e AVC com a TRT. Conclusão: A reposição de testosterona proporciona melhora da saúde sexual do homem e reduz os marcadores da síndrome metabólica. Existe literatura robusta que demonstra a segurança da TRT tanto do ponto de vista do desenvolvimento do câncer de próstata quanto do risco para doenças cardiovasculares.


Keywords


deficiência de testosterona, diagnóstico, tratamento, câncer de próstata, doenças cardiovasculares.

References


Heller, C.G. The Male Climacteric, its Symptomatology, Diagnosis and Treatment. Journal of the American Medical Association. 126(8):472, 1944. Doi:10.1001/Jama.1944.02850430006003.

John P. Mulhall, J.P. et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. The Journal of Urology. Vol. 200, 423-432, August 2018. doi.org/10.1016/j.juro.2018.03.115.

Hall, J.E. Guyton & Hall Tratado de Fisiologia Médica, 17 ed., Rio de Janeiro; Elsevier, 2017. 1176 p.

Kwong, J.C., Krakowsky, Y., Grober, E. Testosterone Deficiency: A Review and Comparison of Current Guidelines. The Journal of Sexual Medicine. 2019 Jun;16(6):812-820. doi:10.1016/j.jsxm.2019.03.262.

Gupta, S.K., Lindemulder, E.A., & Sathyan, G. Modeling of Circadian Testosterone in Healthy Men and Hypogonadal Men. The Journal of Clinical Pharmacology. 2000, 40(7):731–738. doi:10.1177/00912700022009486

Stárka, L., Pospíšilová, H., Hill, M. Free testosterone and free dihydrotestosterone throughout the life span of men. The Journal of Steroid Biochemistry and Molecular Biology. 2009, 116:118–120. doi:10.1016/j.jsbmb.2009.05.008

Herbst, K.L., Bhasin, S. Testosterone action on skeletal muscle. Curr Opin Clin Nutr Metab Care. 2004 May;7(3):271-7. doi: 10.1097/00075197-200405000-00006.

Storer, T.W., Basaria, S., Traustadottir, T et al. Effects of Testosterone Supplementation for 3-Years on Muscle Performance and Physical Function in Older Men. The Journal of Clinical Endocrinology & Metabolism. 2017 Feb 1;102(2):583-593. doi:10.1210/jc.2016-2771.

Mohamad, N.V., Soelaiman, I.N., Chin, K.Y. A concise review of testosterone and bone health. Clinical Interventions in Aging. Volume 11, 2016:1317–1324. doi:10.2147/cia.s115472.

Tuck, S.P., Francis, R.M. Testosterone, Bone and Osteoporosis. Advances in the Management of Testosterone Deficiency, Front Horm Res. 2009;37:123-132. doi: 10.1159/000176049.

Ohlander, S.J., Varghese, B., Pastuszak, A.W. Erythrocytosis Following Testosterone Therapy. Sexual Medicine Reviews. 2018 Jan;6(1):77-85. doi: 10.1016/j.sxmr.2017.04.001.

Levcikova, M., Breza Jr, J., Luha, J. et al. Testosterone replacement therapy (TRT) and its effect on bone marrow. How serious is it and is there a true polyglobulia? Bratislava Medical Journal. 2017, 118(11):654–657. doi:10.4149/bll_2017_124.

Zouboulis, C., Chen, W.C., Thornton, M., Qin, K., Rosenfield, R. (2007). Sexual Hormones in Human Skin. Hormone and Metabolic Research. 2007, 39(2):85–95. doi:10.1055/s-2007-961807.

Xia, B.W., Zhao, S.C., Chen, Z.P. et al. Relationship between serum total testosterone and prostate volume in aging men. Scientific Reports. 2021, 11(1). doi:10.1038/s41598-021-93728-1.

Rastrelli, G., Vignozzi, L., Corona, G., Maggi, M. Testosterone and Benign Prostatic Hyperplasia. Sex Med Rev. 2019 Apr;7(2):259-271. doi: 10.1016/j.sxmr.2018.10.006.

Birzniece, V., Meinhardt, U.J., Umpleby, M.A., et al. 2011). Interaction between Testosterone and Growth Hormone on Whole-Body Protein Anabolism Occurs in the Liver. The Journal of Clinical Endocrinology & Metabolism. 2011 96(4): 1060–1067. doi:10.1210/jc.2010-2521.

Mędraś, M., Brona, A., & Jóźków, P. (2018). The Central Effects of Androgenic-anabolic Steroid Use. Journal of Addiction Medicine. 2018 12(3): 184–192. doi:10.1097/adm.0000000000000395.

Zitzmann, M. The Role of the CAG Repeat Androgen Receptor Polymorphism in Andrology. Front Horm Res. 2009; 37:52-61. doi: 10.1159/000175843.

Kelly, D.M., Jones, T.H. Testosterone and obesity. Obes Rev. 2015 Jul;16(7):581-606. doi: 10.1111/obr.12282.

Dimopoulou, C., Ceausu, I., Depypere, H. et al. EMAS position statement: Testosterone replacement therapy in the aging male‏. Maturitas. 2016 Feb;84:94-9. doi: 10.1016/j.maturitas.2015.11.003.

Alexandersen, P., Christiansen, C. The aging male: testosterone deficiency and testosterone replacement. An up-date. Atherosclerosis. 2004 Apr;173(2):157-69. doi: 10.1016/S0021-9150(03)00242-9.

Wu, F.C., Tajar, A., Pye, S.R. et al. Hypothalamic-Pituitary-Testicular Axis Disruptions in Older Men Are Differentially Linked to Age and Modifiable Risk Factors: The European Male Aging Study. J Clin Endocrinol Metab. 2008 Jul;93(7):2737-45. doi: 10.1210/jc.2007-1972.

Mulligan, T., Frick, M.F., Zuraw, Q.C. et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006 Jul;60(7):762-9. doi: 10.1111/j.1742-1241.2006.00992.x.

Shores, M.M., Smith, N.L., Forsberg, C.W.et al. Testosterone Treatment and Mortality in Men with Low Testosterone Levels. The Journal of Clinical Endocrinology & Metabolism. June 2012, Volume 97, Issue 6:2050–2058. doi.org/10.1210/jc.2011-2591.

Muraleedharan, V., Marsh, H., Kapoor, D. et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013 Oct 21;169(6):725-33. doi: 10.1530/EJE-13-0321.

Salter, C.A., Mulhall, J.P. Guideline of Guidelines: Testosterone Replacement Therapy for Testosterone Deficiency. BJU Int 2019; 124:722–729. doi:10.1111/bju.14899.

Lunenfeld, B.; Mskhalaya, G; Michael Zitzmann, M. et al. Recommendations on the diagnosis, treatment and monitoring of testosterone deficiency in men. Aging Male. 2021 Dec;24(1):119-138. doi: 10.1080/13685538.2021.1962840.

Zitzmann, M. Testosterone, Mood, Behaviour and Quality of Life. Andrology. 2020 Nov;8(6):1598-1605. doi: 10.1111/andr.12867.

Rosen, R.C., Wu, F., Behre, H.M. et al. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME). The Journal of Sexual Medicine. 2017, 14(9):1104–1115. doi:10.1016/j.jsxm.2017.07.004.

di Sante, S., Conner, W., Morgentaler, A. Influence of baseline serum testosterone on changes in body composition in response to testosterone therapy. J Sex Med 2012 Feb;9(2):585-93.

Li, S., Zhao, Y., Yang, Y. et al. Metabolic Effects of Testosterone Replacement Therapy in Patients with Type 2 Diabetes Mellitus or Metabolic Syndrome: A Meta-Analysis. Int J Endocrinol. 2020 Sep 30; 2020: 4732021. doi: 10.1155/2020/4732021.

Hackett, G. Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome. Sex Med Rev. 2019 Jul;7(3):476-490. doi: 10.1016/j.sxmr.2018.12.004.

Anaissie, J., Roberts, N.H., Wang, P. e Yafi, F.A. Testosterone Replacement Therapy and Components of the Metabolic Syndrome. Sexual Medicine Reviews. 2017; 5(2), 200–210. doi:10.1016/j.sxmr.2017.01.003.

Hwang, T.S., Chen, H.E., Tsai, T.F. e Lin, Y.C. Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. International journal of impotence research. 2006; 18(4)400-404. doi:10.1038/sj.ijir.3901446.

Shores, M.M., Smith, N.L., Forsberg, C.W.et al. Testosterone Treatment and Mortality in Men with Low Testosterone Levels. The Journal of Clinical Endocrinology & Metabolism. 2012; 97(6): 2050–2058. doi:10.1210/jc.2011-2591.

Muraleedharan, V., Marsh, H., Kapoor, D. et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. European Journal of Endocrinology. 2013; 169(6):725–733. doi:10.1530/eje-13-0321.

Wenker, E.P., Dupree, J.M., Langille, G.M. et al. The Use of HCG-Based Combination Therapy for Recovery of Spermatogenesis after Testosterone Use. The Journal of Sexual Medicine. 2015; 12(6): 1334–1337. doi:10.1111/jsm.12890.

Whitaker, D.L., Geyer-Kim, G. e Kim, E.D. Anabolic steroid misuse and male infertility: management and strategies to improve patient awareness. Expert Rev Endocrinol Metab. 2021 May;16(3):109-122.

Fink, J., Schoenfeld, B.J., Hackney, A.C. et al. (2020). Human chorionic gonadotropin treatment: a viable option for management of secondary hypogonadism and male infertility. Expert Review of Endocrinology & Metabolism. 2021 Jan;16(1):1-8. doi:10.1080/17446651.2021.1863783.

El-Khatib, F.M., Huynh, L.M., Kopelevich, A. et al. (2021). Comparative assessment of outcomes and adverse effects using two different intramuscular testosterone therapy regimens: 100 mg IM weekly or 200 mg IM biweekly. Int J Impot Res. 2021; Jul 13. doi: 10.1038/s41443-021-00449-0.

Huggins, C and Hodges, V. The Effect of Castration of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate. Cancer Research 1:293-297, 1941.

Behre, H.M., Bohmeyer, J. e Nieschlag, E. (2010). Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clinical Endocrinology. 2010; 40(3):341–349. doi:10.1111/j.1365-2265.1994.tb03929.x.

Morgentaler, A., Bruning, C.O. e DeWolf, W.C. Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996 Dec 18;276(23):1904-6.

Labrie F, Dupont A, Suburu A, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol. 1992;147:846-851. doi:10.1001/jama.1996.03540230054035.

Cooner W.H., Mosley BR, Rutherford CL Jr, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination, and prostate-specific antigen. J Urol. 1990; 143:1146-1150.

Schatzl, G., Madersbacher, S., Thurridl, T. et al. (2001). High-grade prostate cancer is associated with low serum testosterone levels. The Prostate. 2001; 47(1):52–58. doi:10.1002/pros.1046.

Stattin, P., Lumme, S., Tenkanen, L. et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: A pooled prospective study. International Journal of Cancer. 2003; 108(3):418–424. doi:10.1002/ijc.11572.

Massengill, J., Sun, L., Moul, J. et al. (2003). Pretreatment Total Testosterone Level Predicts Pathological Stage in Patients With Localized Prostate Cancer Treated With Radical Prostatectomy. The Journal of Urology. 2003; 169(5):1670–1675. doi:10.1097/01.ju.0000062674.43964.d0.

Roddam, AW, Allen, NE, Appleby P e Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008 Feb 6;100(3):170-83. doi: 10.1093/jnci/djm323.

Haider, A., Zitzmann, M., Doros, G. et al. Incidence of Prostate Cancer in Hypogonadal Men Receiving Testosterone Therapy: Observations from 5-Year Median Followup of 3 Registries. The Journal of Urology. 2015; 193(1):80–86. doi:10.1016/j.juro.2014.06.071.

Morgentaler, A., & Traish, A.M. Shifting the Paradigm of Testosterone and Prostate Cancer: The Saturation Model and the Limits of Androgen-Dependent Growth. European Urology. 2009, 55(2):310–321. doi:10.1016/j.eururo.2008.09.024.

Kaufman, J.M., & Graydon, R.J. Androgen Replacement After Curative Radical Prostatectomy For Prostate Cancer In Hypogonadal Men. The Journal of Urology. 2004; 172(3):920–922. doi:10.1097/01.ju.0000136269.10161.32.

Agarwal, P., Oefelein, M. Testosterone Replacement Therapy After Primary Treatment for Prostate Cancer. The Journal of Urology. 2005; 173(2): 533–536. Doi:10.1097/01.Ju.0000143942.55896.64.

Khera, M., Grober, E.D., Najari, B. et al. Testosterone Replacement Therapy Following Radical Prostatectomy. The Journal of Sexual Medicine. 2009; 6(4):1165–1170. doi:10.1111/j.1743-6109.2009.01161.x.

Sarosdy, M.F. (2007). Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007; 109(3):536–541. doi:10.1002/cncr.22438.

Morgentaler, A., Lipshultz, L.I., Bennett, R. Et al. Testosterone Therapy in Men With Untreated Prostate Cancer. The Journal of Urology. 2011; 185(4):1256–1261. doi:10.1016/j.juro.2010.11.084.

Vigen, R. O’Donnell, R.C., Barón, A.E. et al. Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels. JAMA. 2013; 310(17):1829-1836. doi:10.1001/jama.2013.280386.

Morgentaler, A., Feibus, A., & Baum, N. Testosterone and cardiovascular disease – the controversy and the facts. Postgraduate Medicine. 2015; 127(2):159–165. doi:10.1080/00325481.2015.996111.

Finkle, W.D., Greenland, S., Ridgeway, G.K. et al. Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men. PLoS ONE. 2014; 9(1). e85805. doi:10.1371/journal.pone.0085805.

Corona, G.G., Rastrelli, G., Di Pasquale, G. et al. Endogenous Testosterone Levels and Cardiovascular Risk: Meta-Analysis of Observational Studies. J Sex Med. 2018 Sep;15(9):1260-1271. doi: 10.1016/j.jsxm.2018.06.012.

Corona, G., Rastrelli, G., Di Pasquale, G. et al. Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies. The Journal of Sexual Medicine. 2018; 15(6):820–838. doi:10.1016/j.jsxm.2018.04.641.




DOI: https://doi.org/10.34119/bjhrv5n3-007

Refbacks

  • There are currently no refbacks.